Account
Inquiry
Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight reduction compared to other GLP-1 receptor agonists.
The molecular structure of Tirzepatide features a lysine side chain with PEG modification, enhancing water solubility and biological activity. Its primary function involves acting as a dual agonist at GIP and GLP-1 receptors, making it particularly valuable for metabolic disorder research.
Clinical studies have shown significant weight loss results with Tirzepatide administration. In the SURMOUNT-1 trial, participants experienced average weight reductions of 15-20.9% depending on dosage levels over 72 weeks. These findings highlight its potential for obesity and weight-related health condition research.
Proper storage is essential for maintaining Tirzepatide's research integrity. Store in a cool, dry, dark environment and avoid repeated freeze-thaw cycles. Minimize air exposure and light contact, and aliquot according to experimental requirements rather than storing long-term in solution.
This product is supplied as a white powder in research-grade packaging. Each vial contains 10mg of pure Tirzepatide, with boxes containing 10 vials. The minimum order quantity is 10 vials, suitable for various research applications.
Note: This product is for research use only. Not for human consumption or diagnostic use. Researchers should handle this material following appropriate laboratory safety protocols.
